In Q1 2026, Oramed Pharmaceuticals completed a strategic transition of its oral drug delivery platform and oral insulin program to Lifeward Ltd., acquiring near 50% ownership in the medical device firm and aligning with their commercial portfolio. The company now focuses on managing clinical trials for its oral insulin capsule through subsidiary OraTech under a new agreement. Oramed also maintains significant equity in Alpha Tau Oncology, diversifying exposure into oncology therapeutics. While Oramed’s core innovation lies in oral biologics delivery technology, near-term growth depends on Lifeward’s execution and successful regulatory progress in clinical trials. Risks remain high due to ongoing development challenges, reliance on partnerships, and limited operating scale.